Cargando…

Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?

Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen-Pham, Thanh-Nhan, Lee, Yoon-Kyung, Kim, Hyeoung-Joon, Lee, Je-Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312256/ https://www.ncbi.nlm.nih.gov/pubmed/22481968 http://dx.doi.org/10.1155/2012/397648

Ejemplares similares

Cellular immunotherapy using dendritic cells against multiple myeloma
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
por: Hoang, My-Dung, et al.
Publicado: (2015)

Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells
por: Vo, Manh-Cuong, et al.
Publicado: (2017)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma
por: Chu, Tan-Huy, et al.
Publicado: (2022)

A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
por: Vo, Manh-Cuong, et al.
Publicado: (2017)

Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells
por: Hoang, My-Dung, et al.
Publicado: (2015)

Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin A
por: Tran, Huong Thi Thanh, et al.
Publicado: (2013)

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
por: Vo, Manh-Cuong, et al.
Publicado: (2018)

Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2018)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

Immunotherapy Strategies Against Multiple Myeloma
por: Ma, Jing, et al.
Publicado: (2017)

Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2019)

Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2013)

Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment
por: Jung, Sung-Hoon, et al.
Publicado: (2015)

Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
por: Vu, Son Hai, et al.
Publicado: (2023)

The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2014)

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2020)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Newly Developed Multiple Myeloma in a Patient with Primary T-Cell Lymphoma of Bone
por: Hwang, Jun-Eul, et al.
Publicado: (2008)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Uncarinic Acid C Isolated from Uncaria rhynchophylla Induces Differentiation of Th1-Promoting Dendritic Cells Through TLR4 Signaling
por: Kim, Kyu Sik, et al.
Publicado: (2011)

Multiple myeloma with huge extramedullary plasmacytomas
por: Bae, Soo-Young, et al.
Publicado: (2010)

Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer
por: Park, Min-Ho, et al.
Publicado: (2011)

The Role of Immunotherapy in Multiple Myeloma
por: Kocoglu, Mehmet, et al.
Publicado: (2016)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Immunotherapy for the treatment of multiple myeloma
por: Boussi, Leora S., et al.
Publicado: (2022)

Immunotherapy in myeloma: Why, when and how?
por: van de Donk, Niels W.C.J.
Publicado: (2018)

An Improved Animal Model of Multiple Myeloma Bone Disease
por: Mehdi, Syed Hassan, et al.
Publicado: (2021)

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma
por: Reina-Ortiz, Chantal, et al.
Publicado: (2022)

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen
por: Kim, Su-In, et al.
Publicado: (2022)

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
por: Jung, Sung-Hoon, et al.
Publicado: (2016)

Development of Novel Immunotherapies for Multiple Myeloma
por: Al-Hujaily, Ensaf M., et al.
Publicado: (2016)

Is immunotherapy here to stay in multiple myeloma?
por: Rodríguez-Otero, Paula, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kh69thuk6nnbu17mu9abc80f6t